
Niels Moller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/300257/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reversible insulin resistance in muscle and fat unrelated to the metabolic syndrome in patients with acromegaly. EBioMedicine, 2022, 75, 103763.	6.1	14
2	Oral lactate slows gastric emptying and suppresses appetite in young males. Clinical Nutrition, 2022, 41, 517-525.	5.0	10
3	A macrophage-hepatocyte glucocorticoid receptor axis coordinates fasting ketogenesis. Cell Metabolism, 2022, 34, 473-486.e9.	16.2	34
4	Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes. Endocrine Connections, 2022, 11, .	1.9	15
5	Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes—AÂrandomized placeboâ€controlled crossover trial. Journal of Pineal Research, 2022, 73, .	7.4	10
6	A New Serum Macrophage Checkpoint Biomarker for Innate Immunotherapy: Soluble Signal-Regulatory Protein Alpha (sSIRPI±). Biomolecules, 2022, 12, 937.	4.0	4
7	Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study. Cardiovascular Drugs and Therapy, 2021, 35, 491-503.	2.6	6
8	Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans. Endocrine Research, 2021, 46, 20-27.	1.2	4
9	Acute metabolic effects of melatonin—A randomized crossover study in healthy young men. Journal of Pineal Research, 2021, 70, e12706.	7.4	15
10	Oral 3â€hydroxybutyrate ingestion decreases endogenous glucose production, lipolysis, and hormoneâ€sensitive lipase phosphorylation in adipose tissue in men: a human randomized, controlled, crossover trial. Diabetic Medicine, 2021, 38, e14385.	2.3	11
11	Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997–2017: Time trends in incidence and HbA _{1c} and glucoseâ€lowering drug use before and after hypoglycaemia. Endocrinology, Diabetes and Metabolism, 2021, 4, e00227.	2.4	1
12	β-Lactoglobulin Elevates Insulin and Glucagon Concentrations Compared with Whey Protein—A Randomized Double-Blinded Crossover Trial in Patients with Type Two Diabetes Mellitus. Nutrients, 2021, 13, 308.	4.1	5
13	Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans. Endocrine Connections, 2021, 10, 205-213.	1.9	4
14	β-Lactoglobulin Is Insulinotropic Compared with Casein and Whey Protein Ingestion during Catabolic Conditions in Men in a Double-Blinded Randomized Crossover Trial. Journal of Nutrition, 2021, 151, 1462-1472.	2.9	4
15	Acute ketosis inhibits appetite and decreases plasma concentrations of acyl ghrelin in healthy young men. Diabetes, Obesity and Metabolism, 2021, 23, 1834-1842.	4.4	13
16	Anabolic effects of oral leucine-rich protein with and without β-hydroxybutyrate on muscle protein metabolism in a novel clinical model of systemic inflammation—a randomized crossover trial. American Journal of Clinical Nutrition, 2021, 114, 1159-1172.	4.7	10
17	The Effect of Melatonin on Incretin Hormones: Results From Experimental and Randomized Clinical Studies. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5109-e5123.	3.6	1
18	Extreme insulin resistance during pregnancy: a therapeutic challenge. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	0

#	Article	IF	CITATIONS
19	Miniâ€review: Glucagon responses in type 1 diabetes – a matter of complexity. Physiological Reports, 2021, 9, e15009.	1.7	16
20	3-Hydroxybutyrate administration elevates plasma parathyroid hormone in a pilot human randomized, controlled, cross over trial. Bone, 2021, 153, 116166.	2.9	1
21	SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial. Diabetes, 2021, 70, 800-808.	0.6	32
22	Hyperpolarized [1â€ ¹³ C]pyruvate combined with the hyperinsulinaemic euglycaemic and hypoglycaemic clamp technique in skeletal muscle in a large animal model. Experimental Physiology, 2021, 106, 2412-2422.	2.0	1
23	Growth hormone upregulates ANGPTL4 mRNA and suppresses lipoprotein lipase via fatty acids: Randomized experiments in human individuals. Metabolism: Clinical and Experimental, 2020, 105, 154188.	3.4	12
24	Changes in insulin sensitivity and insulin secretion during pregnancy and post partum in women with gestational diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001728.	2.8	12
25	Increased lipolysis after infusion of acylated ghrelin: a randomized, doubleâ€blinded placeboâ€controlled trial in hypopituitary patients. Clinical Endocrinology, 2020, 93, 672-677.	2.4	3
26	Oral <i>D/L-</i> 3-Hydroxybutyrate Stimulates Cholecystokinin and Insulin Secretion and Slows Gastric Emptying in Healthy Males. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3597-e3605.	3.6	18
27	Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals. Diabetologia, 2020, 63, 2641-2653.	6.3	10
28	A Human Randomized Controlled Trial Comparing Metabolic Responses to Single and Repeated Hypoglycemia in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4699-e4711.	3.6	10
29	Ketone Body, 3-Hydroxybutyrate: Minor Metabolite - Major Medical Manifestations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2884-2892.	3.6	77
30	Acute Hyperketonemia Does Not Affect Glucose or Palmitate Uptake in Abdominal Organs or Skeletal Muscle. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1785-1790.	3.6	7
31	Effects of protein intake prior to carbohydrate-restricted endurance exercise: a randomized crossover trial. Journal of the International Society of Sports Nutrition, 2020, 17, 7.	3.9	9
32	Growth Hormone and Obesity. Endocrinology and Metabolism Clinics of North America, 2020, 49, 239-250.	3.2	25
33	A model mimicking catabolic inflammatory disease; a controlled randomized study in humans. PLoS ONE, 2020, 15, e0241274.	2.5	4
34	Effects of β-hydroxybutyrate on cognition in patients with type 2 diabetes. European Journal of Endocrinology, 2020, 182, 233-242.	3.7	23
35	Soluble <scp>CD</scp> 163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis. Journal of Diabetes Investigation, 2019, 10, 67-72.	2.4	9
36	Effects of short-term prednisolone treatment on indices of lipolysis and lipase signaling in abdominal adipose tissue in healthy humans. Metabolism: Clinical and Experimental, 2019, 99, 1-10.	3.4	9

#	Article	IF	CITATIONS
37	Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5703-5714.	3.6	57
38	Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2581-2592.	3.6	7
39	Immobilization Decreases FOXO3a Phosphorylation and Increases Autophagy-Related Gene and Protein Expression in Human Skeletal Muscle. Frontiers in Physiology, 2019, 10, 736.	2.8	14
40	Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation, 2019, 139, 2129-2141.	1.6	289
41	Unacylated Ghrelin Does Not Acutely Affect Substrate Metabolism or Insulin Sensitivity in Men With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2435-2442.	3.6	3
42	Redundancy in regulation of lipid accumulation in skeletal muscle during prolonged fasting in obese men. Physiological Reports, 2019, 7, e14285.	1.7	10
43	Growth hormone signaling and action in obese versus lean human subjects. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E333-E344.	3.5	12
44	Growth hormone acts along the PPARγ-FSP27 axis to stimulate lipolysis in human adipocytes. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E34-E42.	3.5	42
45	Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis. Diabetologia, 2019, 62, 494-503.	6.3	13
46	Acute intravenous acyl ghrelin infusion induces thirst but does not affect sodium excretion: two randomized, double-blind, placebo-controlled crossover studies in hypopituitary patients. European Journal of Endocrinology, 2019, 181, 23-30.	3.7	7
47	Systemic, but not local, low-grade endotoxinemia increases plasma sCD163 independently of the cortisol response. Endocrine Connections, 2019, 8, 95-99.	1.9	2
48	Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial. Endocrine Connections, 2018, 7, 107-114.	1.9	16
49	Lysyl oxidase and adipose tissue dysfunction. Metabolism: Clinical and Experimental, 2018, 78, 118-127.	3.4	30
50	Escitalopram Ameliorates Hypercortisolemia and Insulin Resistance in Low Birth Weight Men With Limbic Brain Alterations. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 115-124.	3.6	10
51	Ketone Body Infusion Increases Circulating Erythropoietin and Bone Marrow Glucose Uptake. Diabetes Care, 2018, 41, e152-e154.	8.6	11
52	Prolonged fasting-induced metabolic signatures in human skeletal muscle of lean and obese men. PLoS ONE, 2018, 13, e0200817.	2.5	22
53	Effects of 3-hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling during LPS-induced inflammation in humans: anticatabolic impact of ketone bodies. American Journal of Clinical Nutrition, 2018, 108, 857-867.	4.7	89
54	Insulin inhibits autophagy signaling independent of counterregulatory hormone levels but does not affect the effects of exercise. Journal of Applied Physiology, 2018, 125, 1204-1209.	2.5	8

#	Article	IF	CITATIONS
55	A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. American Journal of Clinical Nutrition, 2018, 108, 343-353.	4.7	195
56	Anabolic effects of leucine-rich whey protein, carbohydrate, and soy protein with and without β-hydroxy-β-methylbutyrate (HMB) during fasting-induced catabolism: A human randomized crossover trial. Clinical Nutrition, 2017, 36, 697-705.	5.0	31
57	LPS infusion suppresses serum FGF21 levels in healthy adult volunteers. Endocrine Connections, 2017, 6, 39-43.	1.9	15
58	Acyl Ghrelin Induces Insulin Resistance Independently of GH, Cortisol, and Free Fatty Acids. Scientific Reports, 2017, 7, 42706.	3.3	34
59	Altered gene expression and repressed markers of autophagy in skeletal muscle of insulin resistant patients with type 2 diabetes. Scientific Reports, 2017, 7, 43775.	3.3	57
60	Ketone Body Infusion With 3â€Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study. Journal of the American Heart Association, 2017, 6, .	3.7	144
61	Substrate Metabolism and Insulin Sensitivity During Fasting in Obese Human Subjects: Impact of GH Blockade. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1340-1349.	3.6	22
62	Acute Hypoglycemia in Healthy Humans Impairs Insulin-Stimulated Glucose Uptake and Glycogen Synthase in Skeletal Muscle: A Randomized Clinical Study. Diabetes, 2017, 66, 2483-2494.	0.6	7
63	Metabolic effects of insulin in a human model of ketoacidosis combining exposure to lipopolysaccharide and insulin deficiency: a randomised, controlled, crossover study in individuals with type 1 diabetes. Diabetologia, 2017, 60, 1197-1206.	6.3	5
64	Pancreatic Polypeptide in Parkinson's Disease: A Potential Marker of Parasympathetic Denervation. Journal of Parkinson's Disease, 2017, 7, 645-652.	2.8	6
65	Ketone Body Acetoacetate Buffers Methylglyoxal via a Non-enzymatic Conversion during Diabetic and Dietary Ketosis. Cell Chemical Biology, 2017, 24, 935-943.e7.	5.2	32
66	Shortâ€ŧerm acipimox treatment is associated with decreased cardiac parasympathetic modulation. British Journal of Clinical Pharmacology, 2017, 83, 2671-2677.	2.4	6
67	Effects of insulin-induced hypoglycaemia on lipolysis rate, lipid oxidation and adipose tissue signalling in human volunteers: a randomised clinical study. Diabetologia, 2017, 60, 143-152.	6.3	18
68	Effects of Prednisolone on Serum and Tissue Fluid IGF-I Receptor Activation and Post-Receptor Signaling in Humans. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4031-4040.	3.6	16
69	Effects of Renal Denervation on Insulin Sensitivity and Inflammatory Markers in Nondiabetic Patients with Treatment-Resistant Hypertension. Journal of Diabetes Research, 2017, 2017, 1-9.	2.3	13
70	In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Frontiers in Aging Neuroscience, 2016, 8, 108.	3.4	282
71	Regulation of Lipolysis and Adipose Tissue Signaling during Acute Endotoxin-Induced Inflammation: A Human Randomized Crossover Trial. PLoS ONE, 2016, 11, e0162167.	2.5	51
72	Differential regulation of lipid and protein metabolism in obese vs. lean subjects before and after a 72-h fast. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E224-E235.	3.5	38

#	Article	IF	CITATIONS
73	Reply: Letter to the editor – A dietary amino acid load causes a transient decrease in the function of human neutrophil granulocytes. Clinical Nutrition, 2016, 35, 771.	5.0	0
74	Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3716-3723.	3.6	9
75	Stress hormone release is a key component of the metabolic response to lipopolysaccharide: studies in hypopituitary and healthy subjects. European Journal of Endocrinology, 2016, 175, 455-465.	3.7	6
76	Parity and type 2 diabetes mellitus: a study of insulin resistance and β-cell function in women with multiple pregnancies. BMJ Open Diabetes Research and Care, 2016, 4, e000237.	2.8	11
77	Effect of tighter glycemic control on cardiac function, exercise capacity, and muscle strength in heart failure patients with type 2 diabetes: a randomized study. BMJ Open Diabetes Research and Care, 2016, 4, e000202.	2.8	13
78	Combined Insulin Deficiency and Endotoxin Exposure Stimulate Lipid Mobilization and Alter Adipose Tissue Signaling in an Experimental Model of Ketoacidosis in Subjects With Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes, 2016, 65, 1380-1386.	0.6	13
79	Amino acid supplementation is anabolic during the acute phase of endotoxin-induced inflammation: A human randomized crossover trial. Clinical Nutrition, 2016, 35, 322-330.	5.0	40
80	Impaired hepatic counterregulatory response to insulin-induced hypoglycemia in hepatic denervated pigs. Journal of Clinical and Translational Endocrinology, 2015, 2, 131-136.	1.4	5
81	Hormone and Cytokine Responses to Repeated Endotoxin Exposures—No Evidence of Endotoxin Tolerance After 5 Weeks in Humans. Shock, 2015, 44, 32-35.	2.1	14
82	Hormone and Cytokine Responses to Repeated Endotoxin Exposures—No Evidence of Endotoxin Tolerance After 5 Weeks in Humans. Shock, 2015, 44, 385.	2.1	2
83	Gestational diabetes: A clinical update. World Journal of Diabetes, 2015, 6, 1065.	3.5	215
84	GH signaling in human adipose and muscle tissue during â€~feast and famine': amplification of exercise stimulation following fasting compared to glucose administration. European Journal of Endocrinology, 2015, 173, 283-290.	3.7	16
85	Physical exercise increases autophagic signaling through ULK1 in human skeletal muscle. Journal of Applied Physiology, 2015, 118, 971-979.	2.5	87
86	Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care, 2015, 38, 1089-1098.	8.6	72
87	Circulating acylghrelin levels are suppressed by insulin and increase in response to hypoglycemia in healthy adult volunteers. European Journal of Endocrinology, 2015, 172, 357-362.	3.7	22
88	Intact Pituitary Function is Decisive for the Catabolic Response to TNF-α: Studies of Protein, Glucose and Fatty Acid Metabolism in Hypopituitary and Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 578-586.	3.6	6
89	Rare Presentations of Ketoacidosis: Diabetic Ketoalkalosis and Ketoacidosis Secondary to Fasting and Muscular Dystrophy. Clinical Diabetes, 2015, 33, 37-39.	2.2	7
90	Methodologic Considerations for Quantitative ¹⁸ F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects. Journal of Nuclear Medicine, 2015, 56, 1366-1371.	5.0	18

#	Article	IF	CITATIONS
91	Reduced <i>CD300LG</i> mRNA tissue expression, increased intramyocellular lipid content and impaired glucose metabolism in healthy male carriers of Arg82Cys in <i>CD300LG</i> a novel genometabolic cross-link between <i>CD300LG</i> and common metabolic phenotypes. BMJ Open Diabetes Research and Care, 2015, 3, e000095.	2.8	13
92	Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089–1098. Diabetes Care, 2015, 38, e108-e109.	8.6	1
93	Muscle metabolism and whole blood amino acid profile in patients with liver disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 674-80.	1.2	19
94	Influence of GLP-1 on Myocardial Glucose Metabolism in Healthy Men during Normo- or Hypoglycemia. PLoS ONE, 2014, 9, e83758.	2.5	21
95	Fasting Increases Human Skeletal Muscle Net Phenylalanine Release and This Is Associated with Decreased mTOR Signaling. PLoS ONE, 2014, 9, e102031.	2.5	59
96	Growth Hormone Signaling in Muscle and Adipose Tissue of Obese Human Subjects: Associations With Measures of Body Composition and Interaction With Resveratrol Treatment. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2565-E2573.	3.6	15
97	Sustained AS160 and TBC1D1 phosphorylations in human skeletal muscle 30 min after a single bout of exercise. Journal of Applied Physiology, 2014, 117, 289-296.	2.5	28
98	Adipose Triglyceride Lipase and G0/G1 Switch Gene 2: Approaching Proof of Concept. Diabetes, 2014, 63, 847-849.	0.6	11
99	Using positron emission tomography to study human ketone body metabolism: A review. Metabolism: Clinical and Experimental, 2014, 63, 1375-1384.	3.4	19
100	Growth hormoneâ€induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta Physiologica, 2014, 210, 392-402.	3.8	34
101	Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. Journal of Molecular Endocrinology, 2014, 52, R199-R222.	2.5	282
102	GH signaling in skeletal muscle and adipose tissue in healthy human subjects: impact of gender and age. European Journal of Endocrinology, 2014, 171, 623-631.	3.7	8
103	Effects of 12weeks high dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency – a double-blind, randomized, placebo-controlled trial. Metabolism: Clinical and Experimental, 2014, 63, 1115-1124.	3.4	113
104	Blood Pressure Levels in Male Carriers of Arg82Cys in CD300LG. PLoS ONE, 2014, 9, e109646.	2.5	6
105	High-Dose Resveratrol Supplementation in Obese Men. Diabetes, 2013, 62, 1186-1195.	0.6	402
106	Simultaneous determination of β-hydroxybutyrate and β-hydroxy-β-methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry. Clinical Biochemistry, 2013, 46, 1877-1883.	1.9	35
107	Direct Effects of Locally Administered Lipopolysaccharide on Glucose, Lipid, and Protein Metabolism in the Placebo-Controlled, Bilaterally Infused Human Leg. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2090-2099.	3.6	17
108	Ghrelin- and GH-induced insulin resistance: no association with retinol-binding protein-4. Endocrine Connections, 2013, 2, 96-103.	1.9	4

#	Article	IF	CITATIONS
109	Acute peripheral tissue effects of ghrelin on interstitial levels of glucose, glycerol, and lactate: a microdialysis study in healthy human subjects. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E1273-E1280.	3.5	23
110	ON NO—The Continuing Story of Nitric Oxide, Diabetes, and Cardiovascular Disease. Diabetes, 2013, 62, 2645-2647.	0.6	12
111	Failing Heart of Patients With Type 2 Diabetes Mellitus Can Adapt to Extreme Short-term Increases in Circulating Lipids and Does Not Display Features of Acute Myocardial Lipotoxicity. Circulation: Heart Failure, 2013, 6, 845-852.	3.9	20
112	Whole body metabolic effects of prolonged endurance training in combination with erythropoietin treatment in humans: a randomized placebo controlled trial. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E879-E889.	3.5	28
113	Direct Effects of TNF-α on Local Fuel Metabolism and Cytokine Levels in the Placebo-Controlled, Bilaterally Infused Human Leg. Diabetes, 2013, 62, 4023-4029.	0.6	43
114	Gene expression in skeletal muscle after an acute intravenous GH bolus in human subjects: identification of a mechanism regulating ANGPTL4. Journal of Lipid Research, 2013, 54, 1988-1997.	4.2	22
115	Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain. Frontiers in Neuroenergetics, 2013, 5, 2.	5.3	25
116	Effect of Acute Hyperglycemia on Left Ventricular Contractile Function in Diabetic Patients with and without Heart Failure: Two Randomized Cross-Over Studies. PLoS ONE, 2013, 8, e53247.	2.5	17
117	Insulin resistance after a 72-h fast is associated with impaired AS160 phosphorylation and accumulation of lipid and glycogen in human skeletal muscle. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E190-E200.	3.5	58
118	Metabolic Effects of Short-term GLP-1 Treatment in Insulin Resistant Heart Failure Patients. Experimental and Clinical Endocrinology and Diabetes, 2012, 120, 266-272.	1.2	9
119	Reduced mRNA and Protein Expression of Perilipin A and G0/G1 Switch Gene 2 (GOS2) in Human Adipose Tissue in Poorly Controlled Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1348-E1352.	3.6	27
120	Erythropoietin administration acutely stimulates resting energy expenditure in healthy young men. Journal of Applied Physiology, 2012, 112, 1114-1121.	2.5	17
121	Glucagon-Like Peptide-1 Decreases Intracerebral Glucose Content by Activating Hexokinase and Changing Glucose Clearance during Hyperglycemia. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 2146-2152.	4.3	40
122	The impact of calcineurin inhibitors on insulin sensitivity and insulin secretion: a randomized crossover trial in uraemic patients. Diabetic Medicine, 2012, 29, e440-4.	2.3	15
123	Exenatide Alters Myocardial Glucose Transport and Uptake Depending on Insulin Resistance and Increases Myocardial Blood Flow in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1165-E1169.	3.6	64
124	Evaluation of Functional Erythropoietin Receptor Status in Skeletal Muscle In Vivo: Acute and Prolonged Studies in Healthy Human Subjects. PLoS ONE, 2012, 7, e31857.	2.5	14
125	Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. British Journal of Clinical Pharmacology, 2012, 73, 536-545.	2.4	42
126	Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial. Danish Medical Journal, 2012, 59, A4519.	0.5	46

#	Article	IF	CITATIONS
127	Insulin and GH Signaling in Human Skeletal Muscle In Vivo following Exogenous GH Exposure: Impact of an Oral Glucose Load. PLoS ONE, 2011, 6, e19392.	2.5	25
128	GLUT4 and UBC9 Protein Expression Is Reduced in Muscle from Type 2 Diabetic Patients with Severe Insulin Resistance. PLoS ONE, 2011, 6, e27854.	2.5	74
129	Insulin dose-response studies in severely insulin-resistant type 2 diabetes-evidence for effectiveness of very high insulin doses. Diabetes, Obesity and Metabolism, 2011, 13, 511-516.	4.4	16
130	Time-course effects of physiological free fatty acid surges on insulin sensitivity in humans. Acta Physiologica, 2011, 201, 349-356.	3.8	15
131	Effects of adrenaline on lactate, glucose, lipid and protein metabolism in the placebo controlled bilaterally perfused human leg. Acta Physiologica, 2011, 202, 641-648.	3.8	33
132	Acute Peripheral Metabolic Effects of Intraarterial Leg Infusion of Somatostatin in Healthy Young Men. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2581-2589.	3.6	7
133	Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2405-2413.	3.6	56
134	Fasting, But Not Exercise, Increases Adipose Triglyceride Lipase (ATGL) Protein and Reduces G(0)/G(1) Switch Gene 2 (GOS2) Protein and mRNA Content in Human Adipose Tissue. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1293-E1297.	3.6	68
135	Acute Peripheral Metabolic Effects of Intraarterial Ghrelin Infusion in Healthy Young Men. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 468-477.	3.6	36
136	Growth Hormone (GH)-Induced Insulin Resistance Is Rapidly Reversible: An Experimental Study in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2548-2557.	3.6	43
137	Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. American Journal of Physiology - Renal Physiology, 2011, 301, G269-G277.	3.4	49
138	Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24â€h euglycaemic clamp studies in healthy humans. Diabetic Medicine, 2010, 27, 830-837.	2.3	14
139	Alterations in circulating adiponectin levels occur rapidly after parturition. European Journal of Endocrinology, 2010, 163, 69-73.	3.7	5
140	Decreased Lipid Intermediate Levels and Lipid Oxidation Rates Despite Normal Lipolysis in Patients with Hypothyroidism. Thyroid, 2010, 20, 843-849.	4.5	19
141	Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1096-H1102.	3.2	141
142	Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1220-H1225.	3.2	34
143	Metabolic Effects of Free Fatty Acids During Endotoxaemia in a Porcine Model – Free Fatty Acid Inhibition of Growth Hormone Secretion as a Potential Catabolic Feedback Mechanism. Hormone and Metabolic Research, 2010, 42, 348-352.	1.5	3
144	Reduced Expression of Uncoupling Protein 2 in Adipose Tissue in Patients with Hypothyroidism. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3537-3541.	3.6	8

#	Article	IF	CITATIONS
145	Short-term changes in circulating insulin and free fatty acids affect Nt-pro-BNP levels in heart failure patients. International Journal of Cardiology, 2010, 144, 140-142.	1.7	15
146	Exercise and Fasting Activate Growth Hormone-Dependent Myocellular Signal Transducer and Activator of Transcription-5b Phosphorylation and Insulin-Like Growth Factor-I Messenger Ribonucleic Acid Expression in Humans. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E64-E68.	3.6	25
147	Impact of Fasting on Growth Hormone Signaling and Action in Muscle and Fat. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 965-972.	3.6	36
148	Free Fatty Acids Inhibit Growth Hormone/Signal Transducer and Activator of Transcription-5 Signaling in Human Muscle: A Potential Feedback Mechanism. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2204-2207.	3.6	21
149	Impact of Growth Hormone Receptor Blockade on Substrate Metabolism during Fasting in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4524-4532.	3.6	37
150	Growth hormone and protein metabolism. Clinical Nutrition, 2009, 28, 597-603.	5.0	51
151	The acute effect of a physiological bolus of growth hormone (GH) on insulin signalling pathways in striated muscle in healthy volunteers. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2009, 17, P3.	2.6	0
152	Peroxisome proliferatorâ€activated receptor γ (PPAR) agonism reduces the insulinâ€stimulated increase in circulating interleukinâ€6 in GH replaced GHâ€deficient adults. Clinical Endocrinology, 2009, 71, 363-368.	2.4	5
153	No increased risk of hypoglycaemic episodes during 48Âh of subcutaneous glucagonâ€likeâ€peptideâ€1 administration in fasting healthy subjects. Clinical Endocrinology, 2009, 71, 500-506.	2.4	26
154	Circulating Free Fatty Acids do not Contribute to the Acute Systemic Inflammatory Response. An Experimental Study in Porcine Endotoxaemia. Basic and Clinical Pharmacology and Toxicology, 2009, 105, 319-326.	2.5	3
155	Forearm and leg amino acid metabolism in the basal state and during combined insulin and amino acid stimulation after a 3â€day fast. Acta Physiologica, 2009, 197, 197-205.	3.8	6
156	Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects. Endocrine Reviews, 2009, 30, 152-177.	20.1	804
157	Free Fatty Acids Inhibit Growth Hormone/Signal Transducer and Activator of Transcription-5 Signaling in Human Muscle: A Potential Feedback Mechanism. Molecular Endocrinology, 2009, 23, 735-735.	3.7	0
158	Dose–response effects of free fatty acids on amino acid metabolism and ureagenesis. Acta Physiologica, 2008, 192, 369-379.	3.8	20
159	Acute Effects of Ghrelin Administration on Glucose and Lipid Metabolism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 438-444.	3.6	79
160	Enhancement of Muscle Mitochondrial Function by Growth Hormone. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 597-604.	3.6	74
161	Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans. Diabetes, 2008, 57, 325-331.	0.6	39
162	Ghrelin Infusion in Humans Induces Acute Insulin Resistance and Lipolysis Independent of Growth Hormone Signaling. Diabetes, 2008, 57, 3205-3210.	0.6	138

#	Article	IF	CITATIONS
163	Diabetes and Protein Metabolism. Diabetes, 2008, 57, 3-4.	0.6	55
164	Effects of Glucose, Glycerol, 3-Hydroxybutyrate, Insulin, and Leptin on Placental Growth Hormone Secretion in Placental Explants. Hormone and Metabolic Research, 2008, 40, 189-193.	1.5	8
165	Growth Hormone Signaling in Vivo in Human Muscle and Adipose Tissue: Impact of Insulin, Substrate Background, and Growth Hormone Receptor Blockade. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2842-2850.	3.6	58
166	Serum Ghrelin Levels Are Increased in Hypothyroid Patients and Become Normalized by l-Thyroxine Treatment. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2277-2280.	3.6	36
167	Increased Protein Turnover and Proteolysis Is an Early and Primary Feature of Short-Term Experimental Hyperthyroidism in Healthy Women. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3999-4005.	3.6	19
168	Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1829-E1836.	3.5	87
169	Cardiovascular effects of intravenous ghrelin infusion in healthy young men. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H3020-H3026.	3.2	24
170	The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1724-1728.	3.6	94
171	Dose-Response Effects of Free Fatty Acids on Glucose and Lipid Metabolism during Somatostatin Blockade of Growth Hormone and Insulin in Humans. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1834-1842.	3.6	47
172	Effects of Cortisol on Carbohydrate, Lipid, and Protein Metabolism: Studies of Acute Cortisol Withdrawal in Adrenocortical Failure. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3553-3559.	3.6	131
173	Growth Hormone and Insulin Resistance. Hormone Research in Paediatrics, 2007, 67, 33-36.	1.8	0
174	Growth Hormone Effects on Protein Metabolism. Endocrinology and Metabolism Clinics of North America, 2007, 36, 89-100.	3.2	24
175	Effects of free fatty acids, growth hormone and growth hormone receptor blockade on serum ghrelin levels in humans. Clinical Endocrinology, 2007, 66, 641-645.	2.4	26
176	Protein metabolism in Turner syndrome and the impact of hormone replacement therapy. Clinical Endocrinology, 2007, 67, 413-418.	2.4	5
177	Effects of a 3â€day fast on regional lipid and glucose metabolism in human skeletal muscle and adipose tissue. Acta Physiologica, 2007, 191, 205-216.	3.8	30
178	Medical Emergencies â \in Diabetic Ketoacidosis and Hyperosmolar Hyperglycaemia. , 2007, , 31-37.		1
179	Peripartum maternal and foetal ghrelin, growth hormones, IGFs and insulin interrelations. Clinical Endocrinology, 2006, 64, 502-509.	2.4	21
180	Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. Journal of Internal Medicine, 2006, 260, 11-21.	6.0	72

#	Article	IF	CITATIONS
181	Renal amino acid, fat and glucose metabolism in type 1 diabetic and non-diabetic humans: effects of acute insulin withdrawal. Diabetologia, 2006, 49, 1901-1908.	6.3	28
182	Free fatty acids decrease circulating ghrelin concentrations in humans. European Journal of Endocrinology, 2006, 154, 667-673.	3.7	41
183	Energy expenditure, insulin, and VLDL-triglyceride production in humans. Journal of Lipid Research, 2006, 47, 2325-2332.	4.2	34
184	Kinetics and secretion of placental growth hormone around parturition. European Journal of Endocrinology, 2006, 154, 449-457.	3.7	11
185	Myocardial injury with biomarker elevation in diabetic ketoacidosis. Journal of Diabetes and Its Complications, 2005, 19, 361-363.	2.3	28
186	Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H938-H946.	3.2	20
187	Hyperthyroidism and cation pumps in human skeletal muscle. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E1265-E1269.	3.5	24
188	Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E194-E199.	3.5	57
189	Whole body and forearm substrate metabolism in hyperthyroidism: evidence of increased basal muscle protein breakdown. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E1067-E1073.	3.5	55
190	Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism. European Journal of Endocrinology, 2005, 152, 77-85.	3.7	27
191	Effects of CH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis. European Journal of Endocrinology, 2005, 153, 545-549.	3.7	22
192	Thyroid hormone increases mannan-binding lectin levels. European Journal of Endocrinology, 2005, 153, 643-649.	3.7	22
193	The effect of submaximal exercise on immuno- and bioassayable IGF-I activity in patients with GH-deficiency and healthy subjects. Growth Hormone and IGF Research, 2005, 15, 283-290.	1.1	21
194	Acute exposure to GH during exercise stimulates the turnover of free fatty acids in GH-deficient men. Journal of Applied Physiology, 2004, 96, 747-753.	2.5	33
195	Modulation of basal glucose metabolism and insulin sensitivity by growth hormone and free fatty acids during short-term fasting. European Journal of Endocrinology, 2004, 150, 779-787.	3.7	25
196	Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E488-E494.	3.5	110
197	Growth Hormone and Glucose Homeostasis. Hormone Research in Paediatrics, 2004, 62, 51-55.	1.8	78
198	Moderate hyperthyroidism reduces liver amino nitrogen conversion, muscle nitrogen contents and overall nitrogen balance in rats. European Journal of Clinical Investigation, 2003, 27, 85-92.	3.4	13

#	Article	IF	CITATIONS
199	The Decisive Role of Free Fatty Acids for Protein Conservation during Fasting in Humans with and without Growth Hormone. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4371-4378.	3.6	66
200	Hyperthyroidism Is Associated with Suppressed Circulating Ghrelin Levels. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 853-857.	3.6	90
201	Exercise, hormones, and body temperature. Regulation and action of GH during exercise. Journal of Endocrinological Investigation, 2003, 26, 838-842.	3.3	24
202	Splanchnic Release of Ghrelin in Humans. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 850-852.	3.6	32
203	Effects of growth hormone on lipid metabolism in humans. Growth Hormone and IGF Research, 2003, 13, S18-S21.	1.1	69
204	The Role of Growth Hormone in the Regulation of Protein Metabolism with Particular Reference to Conditions of Fasting. Hormone Research in Paediatrics, 2003, 59, 62-68.	1.8	20
205	Effects of Ageing on Insulin Secretion and Action. Hormone Research in Paediatrics, 2003, 60, 102-104.	1.8	35
206	Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic Heart Disease. Circulation, 2003, 107, e193; author reply e193.	1.6	9
207	The Effect of Growth Hormone on the Insulin-Like Growth Factor System during Fasting. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3292-3298.	3.6	30
208	Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E737-E743.	3.5	36
209	The Effect of Long-Term Pharmacological Antilipolysis on Substrate Metabolism in Growth Hormone (GH)-Substituted GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3274-3278.	3.6	13
210	Elevated Regional Lipolysis in Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4747-4753.	3.6	55
211	Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E172-E177.	3.5	173
212	Plasma ghrelin levels during exercise in healthy subjects and in growth hormone-deficient patients. European Journal of Endocrinology, 2002, 147, 65-70.	3.7	113
213	Cardiovascular Disease and Insulin-Like Growth Factor I. Circulation, 2002, 106, 893-895.	1.6	79
214	Somatropin and Glucose Homeostasis. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2002, 1, 229-234.	1.8	9
215	Effects of GH on protein metabolism during dietary restriction in man. Growth Hormone and IGF Research, 2002, 12, 198-207.	1.1	12
216	Effects of lowering circulating free fatty acid levels on protein metabolism in adult growth hormone deficient patients. Growth Hormone and IGF Research, 2002, 12, 425-433.	1.1	15

#	Article	IF	CITATIONS
217	Chrelin immunoreactivity in human plasma is suppressed by somatostatin. Clinical Endocrinology, 2002, 57, 539-546.	2.4	125
218	Preferential Stimulation of Abdominal Subcutaneous Lipolysis after Prednisolone Exposure in Humans. Obesity, 2002, 10, 774-781.	4.0	33
219	Age Dimorphism in the Association between Growthâ€Hormone Status and the Respiratory Quotient. Obesity, 2002, 10, 284-290.	4.0	2
220	The Effect of Long-Term Pharmacological Antilipolysis on Substrate Metabolism in Growth Hormone (GH)-Substituted GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3274-3278.	3.6	1
221	The Protein-Retaining Effects of Growth Hormone During Fasting Involve Inhibition of Muscle-Protein Breakdown. Diabetes, 2001, 50, 96-104.	0.6	64
222	Assessment of Postabsorptive Renal Glucose Metabolism in Humans With Multiple Glucose Tracers. Diabetes, 2001, 50, 747-751.	0.6	44
223	Pharmacological Antilipolysis Restores Insulin Sensitivity During Growth Hormone Exposure. Diabetes, 2001, 50, 2301-2308.	0.6	122
224	Skeletal muscle glucose uptake, glycogen synthase activity and GLUT 4 content during hypoglycaemia in type 1 diabetic subjects. Scandinavian Journal of Clinical and Laboratory Investigation, 2001, 61, 371-381.	1.2	3
225	Physiological Levels of Glucagon Do Not Influence Lipolysis in Abdominal Adipose Tissue as Assessed by Microdialysis1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2085-2089.	3.6	50
226	Continuation of Growth Hormone (GH) Substitution during Fasting in GH-Deficient Patients Decreases Urea Excretion and Conserves Protein Synthesis1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3120-3129.	3.6	31
227	Physiological Levels of Glucagon Do Not Influence Lipolysis in Abdominal Adipose Tissue as Assessed by Microdialysis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2085-2089.	3.6	48
228	Continuation of Growth Hormone (GH) Substitution during Fasting in GH-Deficient Patients Decreases Urea Excretion and Conserves Protein Synthesis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3120-3129.	3.6	25
229	Growth hormone, IGFâ€I and diabetic angiopathy revisited. Clinical Endocrinology, 2000, 52, 11-12.	2.4	10
230	Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women. Clinical Endocrinology, 2000, 52, 305-312.	2.4	18
231	Reply. Clinical Endocrinology, 2000, 53, 541-541.	2.4	0
232	Effects of leptin on basal and FSH stimulated steroidogenesis in human granulosa luteal cells. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 931-935.	2.8	16
233	Continuation of Growth Hormone (GH) Therapy in GH-Deficient Patients during Transition from Childhood to Adulthood: Impact on Insulin Sensitivity and Substrate Metabolism. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1912-1917.	3.6	66
234	The kidney is an important site for in vivo phenylalanine-to-tyrosine conversion in adult humans: A metabolic role of the kidney. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1242-1246.	7.1	89

#	Article	IF	CITATIONS
235	Effects of oral glucose on systemic glucose metabolism during hyperinsulinemic hypoglycemia in normal man. Metabolism: Clinical and Experimental, 2000, 49, 1598-1603.	3.4	3
236	Continuation of Growth Hormone (GH) Therapy in GH-Deficient Patients during Transition from Childhood to Adulthood: Impact on Insulin Sensitivity and Substrate Metabolism. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1912-1917.	3.6	28
237	Effects of leptin on basal and FSH stimulated steroidogenesis in human granulosa luteal cells. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 931-935.	2.8	9
238	Whole body protein kinetics using Phe and Tyr tracers: an evaluation of the accuracy of approximated flux values. American Journal of Physiology - Endocrinology and Metabolism, 1999, 276, E1194-E1200.	3.5	19
239	Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue. American Journal of Physiology - Endocrinology and Metabolism, 1999, 277, E848-E854.	3.5	50
240	Regional leptin kinetics in humans. American Journal of Clinical Nutrition, 1999, 69, 18-21.	4.7	40
241	Serum Leptin Concentrations During Short-Term Administration of Growth Hormone and Triiodothyronine in Healthy Adults: A Randomised, Double-Blind Placebo-Controlled Study. Hormone and Metabolic Research, 1999, 31, 37-39.	1.5	10
242	Muscle mass and function in thyrotoxic patients before and during medical treatment. Clinical Endocrinology, 1999, 51, 693-699.	2.4	52
243	Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects. Diabetic Medicine, 1999, 16, 861-866.	2.3	52
244	Effects of Growth Hormone Secretagogues on in vivo Substrate Metabolism in Humans. , 1999, , 195-207.		0
245	Hepatic amino- to urea-N clearance and forearm amino-N exchange during hypoglycemic and euglycemic hyperinsulinemia in normal man. Journal of Hepatology, 1999, 30, 819-825.	3.7	9
246	The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism: Clinical and Experimental, 1999, 48, 935-941.	3.4	99
247	Growth hormone treatment improves body fluid distribution in patients undergoing elective abdominal surgery. Clinical Endocrinology, 1998, 49, 597-602.	2.4	8
248	Disruption of the Relationship between Fat Content and Leptin Levels with Aging in Humans1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 931-934.	3.6	83
249	Differential Changes in Free and Total Insulin-Like Growth Factor I after Major, Elective Abdominal Surgery: The Possible Role of Insulin-Like Growth Factor-Binding Protein-3 Proteolysis1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2445-2449.	3.6	55
250	Disruption of the Relationship between Fat Content and Leptin Levels with Aging in Humans. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 931-934.	3.6	80
251	Differential Changes in Free and Total Insulin-Like Growth Factor I after Major, Elective Abdominal Surgery: The Possible Role of Insulin-Like Growth Factor-Binding Protein-3 Proteolysis. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2445-2449.	3.6	24
252	Increased circulating leptin concentrations in insulin-resistant first-degree relatives of patients with non-insulin-dependent diabetes mellitus: relationship to body composition and insulin sensitivity but not to family history of non-insulin-dependent diabetes mellitus. European Journal of Endocrinology, 1997, 136, 173-179.	3.7	47

#	Article	IF	CITATIONS
253	Metabolic Effects and Pharmacokinetics of a Growth Hormone Pulse in Healthy Adults: Relation to Age, Sex, and Body Composition. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3612-3618.	3.6	75
254	Insulin resistance in cardiac syndrome X and variant angina: Influence of physical capacity and circulating lipids. American Heart Journal, 1997, 134, 229-237.	2.7	23
255	Does IGF-I therapy in insulin-dependent diabetes mellitus limit complications?. Lancet, The, 1997, 350, 1188-1189.	13.7	14
256	Hepatic amino nitrogen conversion and organ N-contents in hypothyroidism, with thyroxine replacement, and in hypethyroid rats. Journal of Hepatology, 1997, 26, 409-416.	3.7	8
257	Blockade of the renin-angiotensin-aldosterone system prevents growth hormone-induced fluid retention in humans. American Journal of Physiology - Endocrinology and Metabolism, 1997, 272, E803-E808.	3.5	26
258	Is Skeletal Responsiveness to Thyroid Hormone Altered in Primary Osteoporosis or Following Estrogen Replacement Therapy?. Journal of Bone and Mineral Research, 1997, 12, 78-88.	2.8	15
259	Effects of growth hormone and insulin-like growth factor-I singly and in combination onin vivocapacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats. Hepatology, 1997, 25, 964-969.	7.3	43
260	Effects of Amylin and the Amylin Agonist Pramlintide on Glucose Metabolism. Diabetic Medicine, 1997, 14, S19-S23.	2.3	10
261	Effects of Amylin and the Amylin Agonist Pramlintide on Glucose Metabolism. Diabetic Medicine, 1997, 14, S19-S23.	2.3	10
262	Myocardial insulin resistance in patients with syndrome X Journal of Clinical Investigation, 1997, 100, 1919-1927.	8.2	32
263	Metabolic Effects and Pharmacokinetics of a Growth Hormone Pulse in Healthy Adults: Relation to Age, Sex, and Body Composition. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3612-3618.	3.6	25
264	Skeletal responsiveness to thyroid hormone is not altered at menopause. Bone, 1996, 19, 557-564.	2.9	14
265	Effects of long-term growth hormone (GH) and triiodothyronine (T3) administration on functional hepatic nitrogen clearance in normal man. Journal of Hepatology, 1996, 24, 313-319.	3.7	17
266	Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1996, 45, 211-217.	3.4	19
267	Effects of growth hormone on serum lipids and lipoproteins: Possible significance of increased peripheral conversion of thyroxine to triiodothyronine. Metabolism: Clinical and Experimental, 1996, 45, 1016-1020.	3.4	9
268	Insulin resistance in relatives of NIDDM patients: The role of physical fitness and muscle metabolism. Diabetologia, 1996, 39, 813-822.	6.3	94
269	GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia, 1996, 39, 1227-1232.	6.3	114
270	Glucose turnover, fuel oxidation and forearm substrate exchange in patients with thyrotoxicosis before and after medical treatment. Clinical Endocrinology, 1996, 44, 453-459.	2.4	29

#	Article	IF	CITATIONS
271	Inhibition of muscle glycogen synthase activity and non-oxidative glucose disposal during hypoglycaemia in normal man. Diabetologia, 1996, 39, 226-234.	6.3	16
272	Calorigenic effects of growth hormone: the role of thyroid hormones Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1416-1419.	3.6	39
273	Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1083-1089.	3.6	35
274	Acute effects of the human amylin analog AC137 on basal and insulin- stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1083-1089.	3.6	31
275	Calorigenic effects of growth hormone: the role of thyroid hormones. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1416-1419.	3.6	29
276	Somatostatin enhances insulin-stimulated glucose uptake in the perfused human forearm Journal of Clinical Endocrinology and Metabolism, 1995, 80, 1789-1793.	3.6	30
277	Metabolic effects of growth hormone in humans. Metabolism: Clinical and Experimental, 1995, 44, 33-36.	3.4	76
278	Fuel metabolism in growth hormone-deficient adults. Metabolism: Clinical and Experimental, 1995, 44, 103-107.	3.4	17
279	Forearm Substrate Exchange during Hyperinsulinaemic Hypoglycaemia in Normal Man. Diabetic Medicine, 1995, 12, 218-223.	2.3	7
280	Somatostatin enhances insulin-stimulated glucose uptake in the perfused human forearm. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 1789-1793.	3.6	21
281	Effect of needle biopsy from the vastus lateralis muscle on insulin-stimulated glucose metabolism in humans. American Journal of Physiology - Endocrinology and Metabolism, 1994, 267, E544-E548.	3.5	8
282	Effects of glipizide on glucose metabolism and muscle content of the insulin-regulatable glucose transporter (GLUT 4) and glycogen synthase activity during hyperglycaemia in type 2 diabetic patients. Acta Diabetologica, 1994, 31, 31-36.	2.5	7
283	Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy. Metabolism: Clinical and Experimental, 1994, 43, 579-583.	3.4	36
284	Augmented effect of short-term pulsatile versus continuous insulin delivery on lipid metabolism but similar effect on whole-body glucose metabolism in obese subjects. Metabolism: Clinical and Experimental, 1994, 43, 842-846.	3.4	23
285	Fuel metabolism, energy expenditure, and thyroid function in growth hormone-treated obese women: A double-blind placebo-controlled study. Metabolism: Clinical and Experimental, 1994, 43, 872-877.	3.4	69
286	Effects of growth hormone (GH) administration on functional hepatic nitrogen clearance: studies in normal subjects and GH-deficient patients Journal of Clinical Endocrinology and Metabolism, 1994, 78, 1220-1224.	3.6	15
287	Effects of growth hormone (GH) administration on functional hepatic nitrogen clearance: studies in normal subjects and GH-deficient patients. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 1220-1224.	3.6	17
288	Impact of 2 weeks high dose growth hormone treatment on basal and insulin stimulated substrate metabolism in humans. Clinical Endocrinology, 1993, 39, 577-581.	2.4	35

#	Article	IF	CITATIONS
289	Lipoprotein lipase activity in muscle tissue influenced by fatness, fat distribution and insulin in obese females. European Journal of Clinical Investigation, 1993, 23, 226-233.	3.4	32
290	Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia, 1993, 36, 1079-1086.	6.3	96
291	Insulin resistance in microvascular angina (syndrome X). Lancet, The, 1993, 342, 136-140.	13.7	92
292	Evidence for Increased Sensitivity of Fuel Mobilization to Growth Hormone During Short-Term Fasting in Humans. Hormone and Metabolic Research, 1993, 25, 175-179.	1.5	29
293	Glucose Metabolism in Chronic Renal Failure with Reference to GH Treatment of Uremic Children. Journal of Pediatric Endocrinology and Metabolism, 1993, 6, 53-9.	0.9	8
294	Andrology: Effect of growth hormone administration on circulating levels of luteinizing hormone, follicle stimulating hormone and testosterone in normal healthy men. Human Reproduction, 1993, 8, 1869-1872.	0.9	10
295	Insulin-like growth factors (IGF) I and II and IGF binding proteins 1, 2 and 3 during low-dose growth hormone (GH) infusion and sequential euglycemic and hypoglycemic glucose clamps: studies in GH-deficient patients. European Journal of Endocrinology, 1993, 128, 513-520.	3.7	10
296	Lack of impact of pharmacological growth hormone administration on circulating levels of reproductive hormones during the menstrual cycle in normal women. Fertility and Sterility, 1993, 59, 311-314.	1.0	13
297	Marked effects of sustained low growth hormone (GH) levels on day-to- day fuel metabolism: studies in GH-deficient patients and healthy untreated subjects. Journal of Clinical Endocrinology and Metabolism, 1993, 77, 1589-1596.	3.6	57
298	Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 1993, 77, 1636-1640.	3.6	83
299	Preservation of Inherent Diurnal Serum Insulin-Like Growth Factor Binding Protein 1 Pattern During Low Dose CH Infusion. Hormone and Metabolic Research, 1992, 24, 496-497.	1.5	6
300	Effects of a physiological growth hormone pulse on substrate metabolism in insulin-dependent (type) Tj ETQq0 C	0,rgBT /C	overlock 10 Th
301	Effects of Growth Hormone on Body Fluid Homeostasis. Journal of Pediatric Endocrinology and Metabolism, 1992, 5, .	0.9	0
302	Growth Hormone Effects on Day-to-Day Intermediary Metabolism. Journal of Pediatric Endocrinology and Metabolism, 1992, 5, .	0.9	0
303	Lack of Effects of Hypoglycemia on Glucose Absorption in Healthy Men. Diabetes Care, 1992, 15, 1264-1266.	8.6	4
304	Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy Journal of Clinical Endocrinology and Metabolism, 1992, 74, 1012-1019.	3.6	152
305	Growth hormone secretory capacity and serum insulin-like growth factor I levels in primary infertile, anovulatory women with regular menses. Fertility and Sterility, 1992, 57, 97-101.	1.0	46
306	Octreotide and diabetes: Theoretical and experimental aspects. Metabolism: Clinical and Experimental, 1992, 41, 66-71.	3.4	18

#	Article	IF	CITATIONS
307	Dose-response studies on the metabolic effects of a growth hormone pulse in humans. Metabolism: Clinical and Experimental, 1992, 41, 172-175.	3.4	87
308	Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. Metabolism: Clinical and Experimental, 1992, 41, 728-731.	3.4	73
309	Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. Journal of Clinical Endocrinology and Metabolism, 1992, 74, 1012-1019.	3.6	119
310	Effects of a physiological growth hormone pulse on substrate metabolism in insulin-dependent (type) Tj ETQq0	0 0 rgBT /(Overlock 10 T 16
311	In vivo insulin action and muscle glycogen synthase activity in Type 2 (non-insulin-dependent) diabetes mellitus: effects of diet treatment. Diabetologia, 1992, 35, 777-784.	6.3	65
312	Effects of hyperinsulinemia and hyperglycemia on insulin receptor function and glycogen synthase activation in skeletal muscle of normal man. Metabolism: Clinical and Experimental, 1991, 40, 830-835.	3.4	20
313	Effects of growth hormone on fuel utilization and muscle glycogen synthase activity in normal humans. American Journal of Physiology - Endocrinology and Metabolism, 1991, 260, E736-E742.	3.5	62
314	Fuel Metabolism in a Pig Myocutaneous Island Flap Model. Plastic and Reconstructive Surgery, 1991, 88, 664-672.	1.4	6
315	Carbohydrate Tolerance and Serum Lipids in Acromegaly Before and During Treatment with High Dose Octreotide. Diabetic Medicine, 1991, 8, 517-523.	2.3	38
316	Decreased hepatic glucagon responses in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1991, 34, 521-526.	6.3	29
317	Basal and insulin stimulated substrate metabolism in tumour induced hypoglycaemia; evidence for increased muscle glucose uptake. Diabetologia, 1991, 34, 17-20.	6.3	32
318	Effects of Growth Hormone on Glucose Metabolism. Hormone Research, 1991, 36, 32-35.	1.8	87
319	Short-Term Changes in Serum Insulin-Like Growth Factors (IGF) and IGF Binding Protein 3 after Different Modes of Intravenous Growth Hormone (GH) Exposure in GH-Deficient Patients. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 582-587.	3.6	109
320	Expansion of Extracellular Volume and Suppression of Atrial Natriuretic Peptide after Growth Hormone Administration in Normal Man. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 768-772.	3.6	116
321	24-h profile of serum osteocalcin in growth hormone (GH) deficient patients with and without GH treatment. Growth Regulation, 1991, 1, 153-9.	0.5	6
322	Pharmacological Aspects of Growth Hormone Replacement Therapy: Route, Frequency and Timing of Administration. Hormone Research, 1990, 33, 77-82.	1.8	30
323	Lack of Effects of Angiotensinconverting Enzyme (ACE)â€inhibitors on Glucose Metabolism in Type 1 Diabetes. Diabetic Medicine, 1990, 7, 700-704.	2.3	37
324	Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. American Journal of Physiology - Endocrinology and Metabolism, 1990, 258, E86-E91.	3.5	92

#	Article	IF	CITATIONS
325	Evening <i>Versus </i> Morning Injections of Growth Hormone (GH) in GH-Deficient Patients: Effects on 24-Hour Patterns of Circulating Hormones and Metabolites. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 207-214.	3.6	125
326	Pulsatile Versus Continuous Intravenous Administration of Growth Hormone (GH) in GH-Deficient Patients: Effects on Circulating Insulin-Like Growth Factor-I and Metabolic Indices. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1616-1623.	3.6	103
327	Short-Term Effects of Growth Hormone on Fuel Oxidation and Regional Substrate Metabolism in Normal Man. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1179-1186.	3.6	161
328	Lack of effects of hyperglycemia on the disposal of 3-hydroxybutyrate in insulin-dependent diabetic patients. European Journal of Endocrinology, 1990, 123, 629-632.	3.7	2
329	Circadian patterns of serum insulin-like growth factor (IGF) II and IGF binding protein 3 in growth hormone-deficient patients and age- and sex-matched normal subjects. European Journal of Endocrinology, 1990, 123, 257-262.	3.7	46
330	Substrate metabolism during modest hyperinsulinemia in response to isolated hyperketonemia in in insulin-dependent diabetic subjects. Metabolism: Clinical and Experimental, 1990, 39, 1309-1313.	3.4	11
331	METABOLIC AND HORMONAL RESPONSES TO EXOGENOUS HYPERTHERMIA IN MAN. Clinical Endocrinology, 1989, 30, 651-660.	2.4	44
332	Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia, 1989, 32, 105-110.	6.3	192
333	CONTINUOUS INFUSION OF OCTREOTIDE IN ACROMEGALY. Lancet, The, 1989, 334, 1083-1087.	13.7	25
334	Diabetes-like alterations in hemostatic parameters after growth hormone administration for one week in normal man. The Journal of Diabetic Complications, 1989, 3, 103-106.	0.2	8
335	Contamination of tritiated glucose tracers. Diabète & Métabolisme, 1989, 15, 102-3.	0.3	5
336	Effects of the somatostatin analogue SMS 201–995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrates in normal man. Clinical Science, 1988, 75, 345-350.	4.3	40
337	Observations During a Clinical Trial of Sandostatin® in Acromegalic Patients. , 1988, , 83-87.		3
338	CONTINUOUS SUBCUTANEOUS PUMP INFUSION OF SOMATOSTATIN ANALOGUE SMS 201â€995 VERSUS SUBCUTANEOUS INJECTION SCHEDULE IN ACROMEGALIC PATIENTS. Clinical Endocrinology, 1987, 27, 297-306.	2.4	100
339	Body temperature elevation, exercise and serum prolactin concentrations. European Journal of Endocrinology, 1985, 109, 458-462.	3.7	15
340	Characterization of growth hormone release in response to external heating Comparison to exercise induced release. European Journal of Endocrinology, 1984, 107, 295-301.	3.7	61